First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Julius Strauss; Jean-Laurent Deville; Mario Sznol; Alain Ravaud; Marco Maruzzo; Russell K Pachynski; Theodore S Gourdin; Michele Maio; Luc Dirix; Jeffrey Schlom; Renee N Donahue; Yo-Ting Tsai; XiaoZhe Wang; Yulia Vugmeyster; Frank Beier; Joerg Seebeck; Andreas Schroeder; Sarah Chennoufi; James L Gulley

doi:10.1136/jitc-2022-005813

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

PDF +
Supplementary
Material

Clinical/translational cancer immunotherapy

Original research

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

	Abstract	Full	Pdf
May 2023	413	415	73
Jun 2023	530	535	83
Jul 2023	166	166	62
Aug 2023	200	200	53
Total	1309	1316	271

Main menu

Online download statistics by month:

Online download statistics by month: May 2023 to August 2023

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: May 2023 to August 2023

Read the full text or download the PDF:

Log in using your username and password